FY2026 Earnings Forecast for TVTX Issued By Leerink Partnrs

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at Leerink Partnrs upped their FY2026 earnings per share (EPS) estimates for Travere Therapeutics in a note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn $0.63 per share for the year, up from their prior estimate of $0.52. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.90) per share.

A number of other brokerages have also recently issued reports on TVTX. HC Wainwright increased their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. Barclays lifted their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Piper Sandler increased their price objective on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Scotiabank boosted their target price on shares of Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a research note on Wednesday. Finally, Evercore ISI increased their price target on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.77.

Travere Therapeutics Stock Up 1.0 %

Shares of TVTX opened at $23.43 on Thursday. Travere Therapeutics has a 12 month low of $5.12 and a 12 month high of $25.29. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The company has a 50-day moving average price of $19.06 and a two-hundred day moving average price of $15.95. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -5.09 and a beta of 0.72.

Hedge Funds Weigh In On Travere Therapeutics

A number of institutional investors have recently bought and sold shares of TVTX. Jennison Associates LLC acquired a new position in shares of Travere Therapeutics in the fourth quarter valued at $14,222,000. abrdn plc bought a new position in shares of Travere Therapeutics during the fourth quarter worth approximately $6,829,000. Prudential Financial Inc. lifted its holdings in Travere Therapeutics by 60.5% during the 4th quarter. Prudential Financial Inc. now owns 969,141 shares of the company’s stock worth $16,882,000 after purchasing an additional 365,200 shares during the last quarter. Emerald Advisers LLC boosted its stake in Travere Therapeutics by 19.8% in the 3rd quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock valued at $27,430,000 after purchasing an additional 323,513 shares during the period. Finally, Impax Asset Management Group plc acquired a new stake in shares of Travere Therapeutics during the fourth quarter worth $5,226,000.

Insiders Place Their Bets

In related news, CAO Sandra Calvin sold 15,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at approximately $945,842.94. This trade represents a 21.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric M. Dube sold 11,375 shares of Travere Therapeutics stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $24.04, for a total transaction of $273,455.00. Following the completion of the transaction, the chief executive officer now directly owns 419,173 shares of the company’s stock, valued at approximately $10,076,918.92. This trade represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 218,425 shares of company stock worth $4,674,259. Company insiders own 3.75% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.